EGFR and non-small cell lung carcinoma: Among NSCLC patients, irrespective of EGFR mutation status, median PFS and OS have been shown to be 4.6–5.0 and 12.6–18 months under gefitinib treatment, and 2.7–2.9 and 11.6–12.1 months under erlotinib treatment, respectively 24, 25.